Drugs / MOv18 IgE
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06547840 | Sep 2024 → Jul 2026 overdue | endometrial cancer, ovarian carcinoma, triple-negative breast carcinoma | Epsilogen Ltd | Recruiting | No outcome recorded |
| Phase 1 | NCT02546921 | Feb 2016 → Jun 2021 | — | Cancer Research UK | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2024-07-09 | Epsilogen Ltd | Regulatory Epsilogen announces CTA approval for Phase Ib trial of MOv18 IgE in platinum-resistant ovarian cancer epsilogen.com ↗
Epsilogen, a global leader in the development of immunoglobulin E (IgE) antibodies to treat cancer, today announces that the Clinical Trial Application for the Phase Ib trial of MOv18 IgE has been approved by the UK Medicines and Healthcare products Regulatory Agency (MHRA). |
| 2023-07-25 | Epsilogen Ltd | Results Epsilogen announces successful completion of first ever clinical trial of an IgE antibody; phase I data for MOv18 IgE demonstrates potential of IgE therapy in cancer epsilogen.com ↗
Although the trial was not designed to demonstrate efficacy, tumour shrinkage and an associated fall in CA 125 tumour marker level was seen in one patient. |
| 2020-04-28 | Epsilogen Ltd | Results Encouraging interim data from a phase 1 clinical study evaluating MOv18 IgE in cancer patients with advanced solid tumours presented at the AACR Virtual Annual Meeting epsilogen.com ↗
Results were presented on the first 24 patients enrolled in the study. |
All press releases naming this drug 6 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MOv18 IgE | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02546921 ↗ |
| Action | Deplete | “Once attached, the MOv18 IgE antibody should trigger the body's own immune system to attack and kill the cancer cells.” NCT02546921 ↗ |
| Modality | Monoclonal antibody | “This study is looking at a new drug called MOv18 IgE which belongs to a different class of antibody, the IgE class.” NCT02546921 ↗ |
| Route | Intravenous | “administered by IV infusion” NCT02546921 ↗ |